Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront

Cue Biopharma, Inc.

Upfront payment of $12M; eligible for up to $345M in success-based research, development, and commercial milestones.
BI gets exclusive worldwide license to develop and commercialize CUE-501 and other B cell depletion molecules.
Cue prohibited from developing or commercializing any B cell depletion molecules during the 4-year research term.
BI will pay research support during research term; royalties on net sales subject to standard reductions.
Amendment with Einstein College of Medicine allows sublicense to BI and adjusts upstream payment obligations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.